Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP · NASDAQ Capital Market
+$0.41 today
Vol 0.48M · Avg 0.44M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-53.2%
avg -150.7%
ROIC
-57.2%
avg -160.0%
ROA
-46.7%
avg -87.1%
Analysis
ROA is currently the strongest return metric at -46.7% versus its period average of -87.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Yuval Cohen | Chief Executive Officer & Director | $1.04M | — | 51 | $174,316.00 | 1.39% |
Dominic Smethurst | Chief Medical Officer | $720,988.00 | — | 51 | $89,790.00 | 0.72% |
Sean F. Moran | Chief Financial Officer | $695,745.00 | — | 68 | $96,694.00 | 0.77% |
Ian Hodgson | Chief Operating Officer | — | — | 53 | $51,080.00 | 0.41% |
G. Scott Goeken | General Counsel & Corporate Secretary | — | — | — | — | — |
Nishant C. Saxena | Chief Business Officer | — | — | — | $75,300.00 | 0.60% |
Christina Bertsch | Vice President of Human Resources | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$101,218.50
Sells
14
$1.38M
Net Sentiment
$1.28M
Net selling
Most Active
Cohen Yuval
3 transactions
1–10 of 16
Analysis
Insiders reported 2 buys worth $101,218.50 and 14 sells worth $1.38M over the last 12 months. That adds up to net selling of $1.28M. Cohen Yuval was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | N/A | +42.6% (14yr)4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Forward estimates point to Revenue at +42.6% (14yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Elicio Therapeutics, Inc.
NASDAQ:ELTX
$283.43M
Forte Biosciences, Inc.
NASDAQ:FBRX
$243.83M
Alector, Inc.
NASDAQ:ALEC
$169.87M
Innate Pharma S.A.
NASDAQ:IPHA
$165.27M
Molecular Partners AG
NASDAQ:MOLN
$154.17M
Milestone Pharmaceuticals Inc.
NASDAQ:MIST
$109.08M
Cardiff Oncology, Inc.
NASDAQ:CRDF
$105.29M
PepGen Inc.
NASDAQ:PEPG
$101.68M
Rani Therapeutics Holdings, Inc.
NASDAQ:RANI
$49.65M
Applied Therapeutics, Inc.
APLT
$14.86M
Who manages CRBP?
Corbus Pharmaceuticals Holdings, Inc. (CRBP) lists 7 active executives. The top listed executive is Dominic Smethurst, Chief Medical Officer.
Are CRBP insiders buying or selling?
Recent insider activity shows net buying of $68.00M.
Explore More
Continue the stock analysis
Jump to another research area for this company.